LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: A narrative review on mild behavioural impairment: an exploration into its scientific perspectives.

    Cozza, Mariagiovanna / Boccardi, Virginia

    Aging clinical and experimental research

    2023  Volume 35, Issue 9, Page(s) 1807–1821

    Abstract: In clinical practice, the admission of patients with late-onset psychological and behavioural symptoms is frequent, regardless of the presence or absence of cognitive decline. These symptoms commonly occur in the prodromal stage of dementia and can ... ...

    Abstract In clinical practice, the admission of patients with late-onset psychological and behavioural symptoms is frequent, regardless of the presence or absence of cognitive decline. These symptoms commonly occur in the prodromal stage of dementia and can precede the onset of dementia. While the concept of Mild Cognitive Impairment (MCI) -which is defined as a level of cognitive impairment insufficient to impact daily functioning- is well established, the notion of Mild Behavioural Impairment (MBI) is not yet widely recognized. However, studies have demonstrated that the presence of MBI in both cognitively normal patients and individuals with MCI is associated with an increased risk of dementia progression. Thus, MBI may serve as a neurobehavioral indicator of pre-dementia risk states. This narrative review aims to discuss the evolution of the term, the relevant clinical aspects, and potential biomarkers that may contribute to the clinical definition of MBI. The objective is to assist clinicians in recognizing the diagnosis and differentiating it from psychiatric syndromes, as well as identifying possible etiologies of neurodegeneration.
    MeSH term(s) Humans ; Dementia/etiology ; Dementia/complications ; Neuropsychological Tests ; Cognitive Dysfunction/psychology
    Language English
    Publishing date 2023-07-01
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2104785-6
    ISSN 1720-8319 ; 1594-0667
    ISSN (online) 1720-8319
    ISSN 1594-0667
    DOI 10.1007/s40520-023-02472-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment.

    Cozza, Mariagiovanna / Amadori, Lucia / Boccardi, Virginia

    Journal of the neurological sciences

    2023  Volume 454, Page(s) 120866

    Abstract: Cerebral Amyloid Angiopathy (CAA) is a neurological disorder characterized by the deposition of amyloid plaques in the walls of cerebral blood vessels. This condition poses significant challenges in terms of understanding its underlying mechanisms, ... ...

    Abstract Cerebral Amyloid Angiopathy (CAA) is a neurological disorder characterized by the deposition of amyloid plaques in the walls of cerebral blood vessels. This condition poses significant challenges in terms of understanding its underlying mechanisms, accurate diagnosis, and effective treatment strategies. This article aims to shed light on the complexities of CAA by providing insights into its pathogenesis, diagnosis, and treatment options. The pathogenesis of CAA involves the accumulation of amyloid beta (Aβ) peptides in cerebral vessels, leading to vessel damage, impaired blood flow, and subsequent cognitive decline. Various genetic and environmental factors contribute to the development and progression of CAA, and understanding these factors is crucial for targeted interventions. Accurate diagnosis of CAA often requires advanced imaging techniques, such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans, to detect characteristic amyloid deposits in the brain. Early and accurate diagnosis enables appropriate management and intervention strategies. Treatment of CAA focuses on preventing further deposition of amyloid plaques, managing associated symptoms, and reducing the risk of complications such as cerebral hemorrhage. Currently, there are no disease-modifying therapies specifically approved for CAA. However, several experimental treatments targeting Aβ clearance and anti-inflammatory approaches are being investigated in clinical trials, offering hope for future therapeutic advancements.
    MeSH term(s) Humans ; Amyloid beta-Peptides/metabolism ; Plaque, Amyloid/pathology ; Cerebral Amyloid Angiopathy/complications ; Cerebral Amyloid Angiopathy/diagnostic imaging ; Cerebral Amyloid Angiopathy/therapy ; Brain/pathology ; Cerebral Hemorrhage/complications ; Alzheimer Disease/complications
    Chemical Substances Amyloid beta-Peptides
    Language English
    Publishing date 2023-11-02
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2023.120866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top